HC Wainwright Has Lowered Expectations for Aptose Biosciences (NASDAQ:APTO) Stock Price

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) had its price target cut by HC Wainwright from $7.00 to $2.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock.

Separately, StockNews.com started coverage on Aptose Biosciences in a research note on Wednesday, November 13th. They issued a “hold” rating for the company.

Aptose Biosciences Stock Performance

Shares of Aptose Biosciences stock opened at $0.24 on Wednesday. Aptose Biosciences has a one year low of $0.23 and a one year high of $2.91. The stock’s fifty day moving average is $0.38 and its 200 day moving average is $0.62. The stock has a market cap of $4.42 million, a P/E ratio of -0.09 and a beta of 1.26.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC purchased a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences at the end of the most recent quarter. 26.62% of the stock is owned by institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.